Immunocore Holdings plc
IMCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Immunocore Holdings plc (IMCR) is listed under Biotechnology. Valued at $1.47B, IMCR is a small-cap name in its sector. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Market Cap
$1.47B
Beta
0.74
P/E (TTM)
—
P/E (Fwd)
-42.97
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.67
ROE
-7.1%
ROA
-0.9%
Cash
$844.9M
Total Debt
$435.7M
Free CF
$58.6M
52W Change
-20.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $844.9M in cash comfortably exceeding the $435.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $58.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -7.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $174.4M (2022) to $400.0M (2025), reflecting a 129% increase over the period.
As with any equity investment, IMCR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immunocore Holdings plc's trajectory.